COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2. Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Multi-year studies are underway to further investigate the long-term effects of the disease.
To enhance your search results you can use the various filters available such as mode (online/ on-site.
Remdesivir , is approved in India for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease....
While the COVID-19 situation is still evolving, we are doing everything we can to help healthcare providers in LMICs be prepared to provide life-saving care to patients in need. With this in...
As the incidence of COVID-19 cases continue to rise, we will need multiple approaches to effectively deal with this pandemic. Clinicians are evaluating Favipiravir for use in mild-to-moderat...
Indian Medical Association Rajasthan (IMA Raj) welcomes doctors to view a recorded session on “Clinical & Pulmonary COVID-19 complications” held on 13th Sep 2020, where...
Cases of COVID-19 are steadily rising in India, and because there is limited clinical experience around treatment options it becomes critical to share knowledge. Indian Medical Association Ma...
While the COVID-19 situation is still evolving, we are doing everything we can to help healthcare providers in LMICs be prepared to provide life-saving care to patients in need. With this in...
Welcome to an exciting international exchange of experiences on "Remdesivir for the Treatment of Severe COVID-19"; the live webinar was held on 28th August 2020. In India,...
In India, Remdesivir has been approved for emergency use in patients hospitalized with severe COVID-19. There is a need to understand and share experience on the use of this drug. We welcome you to vi...
The challenges of conducting trials against the backdrop of the COVID-19 pandemic will continue as we collectively journey into the “new normal”. Welcome to the recorded webinar on &...
